Poop pills plus immunotherapy: new hope for lung cancer?
NCT ID NCT07432984
First seen Mar 10, 2026 · Last updated Apr 28, 2026 · Updated 5 times
Summary
This study tests whether a fecal microbiota transplant (FMT) combined with the drug tislelizumab can help people with advanced non-small cell lung cancer whose disease got worse after standard immunotherapy. The goal is to see if changing gut bacteria can restore the immune system's ability to fight cancer. The trial will enroll 15 participants and focus on safety and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.